Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Atavistik Bio, Inc
Eli Lilly and Company
Stemline Therapeutics, Inc.
AstraZeneca
Eli Lilly and Company
Eli Lilly and Company
AstraZeneca
Stanford University
Hoffmann-La Roche
Novartis
Hoffmann-La Roche
Myriad Genetic Laboratories, Inc.
Syndax Pharmaceuticals
ChineseAMS
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Sinocelltech Ltd.
Concure Oncology-Breast Microseed Inc.
Instituto Nacional de Cancer, Brazil
University of British Columbia
University of Kansas Medical Center
Medifocus, Inc.
BBB-Therapeutics B.V.
University College, London
Faculdade de Medicina do ABC
Medco Health Solutions, Inc.